Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 4, 2018

Paradigm Spine gets FDA approval for disposable spinal instruments

The US Food and Drug Administration (FDA) has awarded a pre-market supplemental approval (PMA) to Paradigm Spine’s disposable instrument set for its Class III spinal device.

The US Food and Drug Administration (FDA) has awarded a pre-market supplemental approval (PMA) to Paradigm Spine’s disposable instrument set for its Class III spinal device.

The coflex Interlaminar Stabilization device is understood to be the first spinal instrument to obtain FDA approval.

Paradigm Spine said that its kit is a posterior lumbar motion preservation solution and demonstrated long-term outcomes for patients suffering from moderate to severe spinal stenosis.

The simplified set will comprise injection moulded instruments in a pre-sterilised peel pack. It comes with a future option for implantation of coflex that is considered effective in the outpatient care setting.

“These kits are simple, disposable, sterile, and will reduce both financial and operational burdens on facilities.”

Paradigm Spine chairman and CEO Marc Viscogliosi said: “We are thrilled to have the first PMA-approved disposable instrument kit for a Class III spinal device, and be able to offer this resource to our surgeon customers, further improving their experience with coflex.

“These kits are ideal for outpatient and ambulatory surgery centres because they are simple, disposable, sterile, and will reduce both financial and operational burdens on facilities.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“In addition, through a more streamlined manufacturing process, the kits are created to have a low carbon footprint, so they benefit physicians without causing excessive harm to the environment.”

Lumbar spinal stenosis, which affects 1.6 million people in the US each year, is a debilitating and degenerative condition characterised by leg and back pain, leg numbness and weakness.

The disease is usually treated through surgical decompression alone or in combination with lumbar fusion.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU